The other is an injection of antibodies — sold under the brand name Beyfortus, known by its scientific name nirsevimab — given to infants before their first RSV season, and a few high-risk ...
Paris, October 9, 2024. Sanofi advances its ambition to protect all infants from respiratory syncytial virus (RSV) disease with new Beyfortus (nirsevimab) data to be presented at the Infectious ...
Some results have been hidden because they may be inaccessible to you